Report LibraryAll Reports
Datamonitor Healthcare Oncology: Breast Cancer: HR+/HER2- Disease Coverage
Retail Price: $22,000.00*BioMedTracker Subscriber Price: $15,000.00 - click here to log in
May 09, 2018Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer is defined by the overexpression of estrogen or progesterone receptors, or both, and a lack of HER2 expression. Overexpression of hormone receptors allows estrogen and progesterone to drive tumor growth and proliferation. Endocrine therapy remains the standard treatment for advanced HR+/HER2- breast cancer, with steroidal and non-steroidal aromatase inhibitors making up the most common treatment choices.
This Datamonitor Healthcare Disease Coverage report contains Forecast, Treatment, Epidemiology, Marketed Drugs, and Pipeline modules.
|Disease Group Covered:||Oncology|